168 related articles for article (PubMed ID: 26946450)
1. Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System.
Mast MR; Walraven I; Hoekstra T; Jansen AP; van der Heijden AA; Elders PJ; Heine RJ; Dekker JM; Nijpels G; Hugtenburg JG
Diabet Med; 2016 Jun; 33(6):794-802. PubMed ID: 26946450
[TBL] [Abstract][Full Text] [Related]
2. Distinct trajectories of HbA
Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
[TBL] [Abstract][Full Text] [Related]
3. Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: The CREDIT study.
Balkau B; Calvi-Gries F; Freemantle N; Vincent M; Pilorget V; Home PD
Diabetes Res Clin Pract; 2015 Jun; 108(3):432-40. PubMed ID: 25818885
[TBL] [Abstract][Full Text] [Related]
4. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
Montvida O; Shaw JE; Blonde L; Paul SK
Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
[TBL] [Abstract][Full Text] [Related]
5. Patient-level predictors of achieving early glycaemic control in Type 2 diabetes mellitus: a population-based study.
Svensson E; Baggesen LM; Thomsen RW; Lyngaa T; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabet Med; 2016 Nov; 33(11):1516-1523. PubMed ID: 27412570
[TBL] [Abstract][Full Text] [Related]
6. The relationship between glycated haemoglobin and blood glucose-lowering treatment trajectories in type 2 diabetes: The Fremantle Diabetes Study Phase II.
Davis TME; Davis W
Diabetes Obes Metab; 2024 Jan; 26(1):283-292. PubMed ID: 37795655
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal HbA1c patterns before the first treatment of diabetes in routine clinical practice: A latent class trajectory analysis.
Nicolaisen SK; le Cessie S; Thomsen RW; Witte DR; Dekkers OM; Sørensen HT; Pedersen L
Diabetes Res Clin Pract; 2024 Jun; 212():111722. PubMed ID: 38815656
[TBL] [Abstract][Full Text] [Related]
8. HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups.
Sidorenkov G; van Boven JFM; Hoekstra T; Nijpels G; Hoogenberg K; Denig P
Diabetes Obes Metab; 2018 Aug; 20(8):1957-1964. PubMed ID: 29687577
[TBL] [Abstract][Full Text] [Related]
9. Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study.
Maguire A; Mitchell BD; Ruzafa JC
BMC Endocr Disord; 2014 Aug; 14():73. PubMed ID: 25163796
[TBL] [Abstract][Full Text] [Related]
10. Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change.
Hirst JA; Stevens RJ; Farmer AJ
PLoS One; 2014; 9(3):e92458. PubMed ID: 24667212
[TBL] [Abstract][Full Text] [Related]
11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
12. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
13. Rates of glycaemic deterioration in a real-world population with type 2 diabetes.
Donnelly LA; Zhou K; Doney ASF; Jennison C; Franks PW; Pearson ER
Diabetologia; 2018 Mar; 61(3):607-615. PubMed ID: 29260253
[TBL] [Abstract][Full Text] [Related]
14. HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
Bongaerts B; Kuss O; Bonnet F; Chen H; Cooper A; Fenici P; Gomes MB; Hammar N; Ji L; Khunti K; Medina J; Nicolucci A; Shestakova MV; Watada H; Rathmann W
Diabetes Obes Metab; 2023 Jul; 25(7):1890-1899. PubMed ID: 36906837
[TBL] [Abstract][Full Text] [Related]
15. Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.
Punthakee Z; Miller ME; Simmons DL; Riddle MC; Ismail-Beigi F; Brillon DJ; Bergenstal RM; Savage PJ; Hramiak I; Largay JF; Sood A; Gerstein HC;
Diabetologia; 2014 Oct; 57(10):2030-7. PubMed ID: 24985147
[TBL] [Abstract][Full Text] [Related]
16. Temporal changes in glycaemic thresholds for treatment intensification in type 2 diabetes in an urban Australian setting: the Fremantle Diabetes Study.
Davis TME; Chubb SAP; Curtis BH; Barraclough H; Davis WA
Intern Med J; 2018 Oct; 48(10):1215-1221. PubMed ID: 29230931
[TBL] [Abstract][Full Text] [Related]
17. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
19. Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience.
Hanefeld M; Fleischmann H; Schiffhorst G; Bramlage P
Diabetes Technol Ther; 2014 Apr; 16(4):241-6. PubMed ID: 24229089
[TBL] [Abstract][Full Text] [Related]
20. Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey.
Gerber PA; Spirk D; Brändle M; Thoenes M; Lehmann R; Keller U
Swiss Med Wkly; 2011; 141():w13218. PubMed ID: 21735364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
